title: [Clinicopathologic features and prognosis of triple negative breast cancer].
abstract: OBJECTIVE
  To analyze the clinicopathologic features and prognosis of triple negative breast cancer.
  
  
  METHODS
  The clinical datas of 477 patients of primary breast cancer which were diagnosed by pathology in the 4th Hospital of Hebei Medical University from Jan. 2004 to Dec. 2004 were analyzed. All of the patients were divided into two groups according to the results of immunohistochemistry: one was triple negative breast cancer (TNBC) which included estrogen receptor (ER) negative, progesterone receptor (PR) negative and human epidermal growth factor receptor (HER2) negative and other was non-triple negative breast cancer. We compared TNBC with the group of non-triple negative breast cancer in the clinicopathologic features. The disease-free survival (DFS) and overall survival (OS) were analyzed by Kaplan-Meier method.
  
  
  RESULTS
  Of the 477 patients, 12.6% (60/477) was TNBC patients in which 76.7% of age was younger than fifty years(46/60), 28.3% of T > 5 cm (17/60), 68.3% of lymph nodes metastasis (41/60), 31.7% of grade III (19/60) and 13.3% of family history of breast cancer (8/60), (P < 0. 05). Till June 2008, the median time of follow-up was 48 months (42-54 months). Local recurrence or distant metastasis were 26.7% (16/60) of TNBC which was higher than 15.3% (64/417) of non-triple negative cases; DFS was 68.3% in TNBC group and 79.6% in the non-triple negative breast cancer group. The OS was 81.7% in TNBC group and 90.9% in the non-triple negative breast cancer group (Log-Rank = 3.917, P = 0.048; Log-Rank = 4.838, P = 0.028).
  
  
  CONCLUSIONS
  These patients of triple negative breast carcinoma were usually young (age < 50), with tumor growth fast, much more invasion and poorly prognosis.
authors.affiliation: Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
authors.forename: Tao
authors.initials: T
authors.lastname: Zhou
authors.forename: Li
authors.initials: L
authors.lastname: Yang
authors.forename: Guo-ming
authors.initials: GM
authors.lastname: Ma
authors.forename: Chun-xiao
authors.initials: CX
authors.lastname: Li
authors.forename: Yang
authors.initials: Y
authors.lastname: Bai
authors.forename: Ji-an
authors.initials: JA
authors.lastname: Zhao
authors.forename: Xiao-ling
authors.initials: XL
authors.lastname: Wang
authors.forename: Cui-zhi
authors.initials: CZ
authors.lastname: Geng
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D055815:Young Adult
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human